PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Reich, Kristian
TI  - Apremilast Was Associated with an Acceptable Safety Profile in ESTEEM Trials
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 6--7
VI  - 14
IP  - 37
4099  - http://mdc.sagepub.com/content/14/37/6.short
4100  - http://mdc.sagepub.com/content/14/37/6.full
AB  - Two phase 3 randomized controlled trials were performed to evaluate the safety and efficacy of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis. This article discusses the safety analysis from the pooled data of the ESTEEM 1 [NCT01194219] and ESTEEM 2 trials [NCT01232283].